[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hepotacellular-carcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hepotacellular-carcinoma":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,41,73],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100619399","hepatobiliary-and-pancreatic-tumor-biobank-100619399",false,"NCT07344116","Hepatobiliary and Pancreatic Tumor Biobank","Establishment of a Hepatobiliary and Pancreatic Tumor Biobank at a Single Academic Medical Center","Inclusion Criteria:\n\n* Adults aged 18 years or older.\n* Patients diagnosed with hepatobiliary or pancreatic malignant tumors, including but not limited to hepatocellular carcinoma, cholangiocarcinoma, gallbladder cancer, and pancreatic cancer; or patients with benign hepatobiliary or pancreatic diseases; or selected healthy volunteers.\n* Receiving medical care or health evaluation at the Second Affiliated Hospital of Zhejiang University School of Medicine.\n* Able and willing to provide written informed consent, unless waived or exempted by the institutional ethics committee for retrospective samples.\n* Willing to allow collection and storage of biological specimens and related clinical data for research purposes.\n\nExclusion Criteria:\n\n* Age younger than 18 years.\n* Unable to provide informed consent and without a legally authorized representative.\n* Presence of conditions that, in the opinion of the investigators, make participation inappropriate or infeasible.\n* Refusal to allow the collection or use of biological specimens or clinical data for research.",true,"ALL","18 Years",{"count":20,"type":21},300,"ESTIMATED","5 Years","OBSERVATIONAL","This study aims to establish a hepatobiliary and pancreatic tumor biobank at the Second Affiliated Hospital of Zhejiang University School of Medicine. The biobank will systematically collect and store human biological samples, such as blood, tissue, bile, and other body fluids, together with relevant clinical and follow-up information from patients with hepatobiliary and pancreatic tumors, benign hepatobiliary and pancreatic diseases, and selected healthy volunteers.\n\nThe collection of samples will be performed without changing routine medical care and will not involve any experimental treatment or additional invasive procedures for research purposes. Biological samples will be obtained during standard clinical diagnosis and treatment, or from remaining specimens after routine clinical use.\n\nAll samples and data will be coded and stored according to ethical and legal requirements to protect participants' privacy. The biobank is intended to serve as a long-term research resource to support future basic, translational, and clinical research on hepatobiliary and pancreatic diseases, with the goal of improving understanding of disease mechanisms and advancing medical research in this field.",[26,27,28],"Hepotacellular Carcinoma","Cholangiocarcinoma","Pancreatic Cancer","NOT_YET_RECRUITING","2026-01-07",{"date":32,"type":33},"2026-01-15","ACTUAL",{"date":35,"type":21},"2026-01-01",{"date":37,"type":21},"2040-12-31",{"name":39,"class":40},"Second Affiliated Hospital, School of Medicine, Zhejiang University","OTHER",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":55,"conditions":56,"keywords":57,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100614637","phase-1-multimodal-deep-learning-for-postoperative-liver-cancer-risk-stratification-and-intervention-100614637","NCT07282184","Multimodal Deep Learning for Postoperative Liver Cancer Risk Stratification and Intervention","A Multimodal Deep Learning-Driven Study for Perioperative Risk Stratification and Precision Intervention in Hepatocellular Carcinoma Recurrence","Inclusion Criteria:\n\n* Age and Consent: Patients aged 18-75 years who are able to understand and voluntarily sign an Informed Consent Form.\n* Diagnosis: Clinical diagnosis of BCLC stage 0-A hepatocellular carcinoma, confirmed by histopathology or non-invasive imaging criteria per guidelines.\n* Surgical Candidacy: Scheduled to undergo curative-intent liver resection.\n* Risk Stratification: Predicted as high-risk for aggressive recurrence by the pre-operative multimodal deep learning model (PRE score ≥ 0.5).\n* Liver Function: Child-Pugh liver function class A (score ≤ 7).\n* Performance Status: ECOG Performance Status of 0 or 1.\n* Imaging Requirement: Availability of a standard pre-operative MRI scan (including non-contrast, arterial, portal venous, and delayed phases) performed within 1 month prior to enrollment, with acceptable image quality.\n* Follow-up Commitment: Willing and able to comply with the study procedures and scheduled follow-up for at least 2 years.\n\nExclusion Criteria:\n\n* Pathology: Postoperative pathological confirmation of non-HCC malignancy (e.g., cholangiocarcinoma, combined hepatocellular-cholangiocarcinoma).\n* Other Malignancies: History of other active malignancies within the past 5 years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin cancer, or other cancers with a very low risk of recurrence.\n* Early Mortality\u002FLoss: Death from any cause or loss to follow-up within 90 days after surgery.\n* Contraindications to Protocol Therapy: Known hypersensitivity to any component of the neoadjuvant therapy regimen (e.g., oxaliplatin, fluorouracil, PD-1 inhibitors, lenvatinib).\n* Severe, uncontrolled medical conditions including but not limited to: Uncontrolled cardiac disease (e.g., NYHA Class III or IV heart failure), Severe renal dysfunction, Uncontrolled hypertension.\n* Inability to Participate: Any condition that, in the opinion of the investigator, would compromise the patient's ability to participate in the study or interfere with the evaluation of the study objectives.","75 Years",{"count":50,"type":21},144,"INTERVENTIONAL",[53,54],"PHASE1","PHASE2","This study is for patients with early-stage liver cancer who are planning to have surgery. The goal of this research is to see if a personalized treatment plan, guided by a computer model (an artificial intelligence tool), can help prevent the cancer from coming back after surgery.\n\nFirst, the computer model will analyze each patient's medical images and health data to predict their personal risk of the cancer returning. Patients whom the model predicts have a high risk of the cancer coming back will be offered a special treatment plan. This plan involves receiving medication (neoadjuvant therapy) before surgery and additional medication (adjuvant therapy) after surgery. The effectiveness of this plan will be compared to the standard approach of surgery alone.\n\nThe main goal is to see if this new, personalized plan can better prevent the cancer from returning within 2 years after surgery. The study will also closely monitor the safety of the medications used.\n\nAll patients in the study will be followed closely for 2 years with regular scans and check-ups to monitor their health.",[26],[58,59,60,61],"deep learning","recurrence pattern","Hepatocellular Carcinoma","Neoadjuvant Therapy","RECRUITING","2025-12-17",{"date":65,"type":33},"2025-12-18",{"date":67,"type":33},"2025-10-26",{"date":69,"type":21},"2028-06-30",{"name":71,"class":40},"Tongji Hospital",1,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":48,"enrollmentInfo":81,"targetDuration":83,"studyType":23,"phases":4,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":72},"100604270","the-role-of-serum-akr1b10-in-early-warning-of-hepatocellular-carcinoma-in-cirrhosis-patients-100604270","NCT07147335","The Role of Serum AKR1B10 in Early Warning of Hepatocellular Carcinoma in Cirrhosis Patients","The Role of Serum AKR1B10 in Early Warning of Hepatocellular Carcinoma in Cirrhosis Patients ------ Risk Early Warning and Follow-up Study","AKR1B10","Inclusion Criteria:\n\n* Meets diagnostic criteria for liver cirrhosis and chronic hepatitis\n* Aged 18-75 years, regardless of gender\n* Willing to participate in the study and provides signed informed consent\n* Has not participated in other clinical trials within the last 3 months\n\nExclusion Criteria:\n\n* Pregnancy or lactation\n* Incomplete clinical data, serological or imaging records\n* Lost to follow-up prior to reaching the observational endpoints\n* Aged \\\u003C18 years or \\>75 years\n* Concurrent severe systemic diseases (e.g., involving cardiovascular, cerebral, pulmonary, renal, or hematopoietic systems)\n* Current or recent (within 3 months) participation in other clinical trials\n* Diagnosed with hepatocellular carcinoma (HCC)",{"count":82,"type":21},800,"3 Years","Hepatocellular carcinoma (HCC) is a globally prevalent malignancy. In its characteristic \"chronic hepatitis-liver cirrhosis-HCC\" progression trilogy, patients with cirrhosis demonstrate a 5-year HCC incidence rate of 3%-5%, yet effective monitoring strategies remain lacking. Current early diagnosis relies on the combination of imaging techniques and serum alpha-fetoprotein (AFP), but AFP measurements are frequently confounded by pregnancy and liver diseases, resulting in suboptimal sensitivity and specificity. In recent years, novel tumor biomarkers such as AKR1B10 (Aldo-keto reductase family 1 member B10) have been examined. This multicenter prospective cohort study aims to validate the predictive value of serum AKR1B10 for malignant transformation in cirrhosis-HCC progression, and evaluate its combined efficacy with existing risk prediction models, ultimately establishing a high-sensitivity early diagnostic strategy for clinical implementation.",[86,26],"Cirrhosis",[79,88,89],"Hepotacellular carcinoma","cirrhosis","2025-08-28",{"date":92,"type":33},"2025-08-29",{"date":94,"type":33},"2025-05-16",{"date":96,"type":21},"2028-03-31",{"name":98,"class":40},"The First Affiliated Hospital of University of South China"]